{
    "nct_id": "NCT05222984",
    "official_title": "A Phase Ib Open Label Study of Navitoclax in Combination With Venetoclax + Decitabine in Relapsed/Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax",
    "inclusion_criteria": "* Documented informed consent of the participant and/or legally authorized representative\n* For participants under the age of 18 years, documentation of adolescent assent by the participant and consent of both parents or guardian\n* Adults aged >= 18 years\n* Adolescent patients aged >= 16 years and < 18 years weighing at least 45 kg who have no other standard-of-care option for treatment\n* Eastern Cooperative Oncology Group (ECOG) =< 2\n* Patients with histologically confirmed AML, according to World Health Organization (WHO) criteria, with refractory/relapsed (R/R) disease following a venetoclax-containing regimen who are ineligible for therapies known to be effective for treatment of their AML.\n\n  * Patients with extramedullary disease may be included if they also have marrow involvement\n  * Patients with acute promyelocytic leukemia (APL) will not be eligible\n* Fully recovered from the acute toxic effects (except alopecia) to =< grade 1 of prior anti-cancer therapy\n* Ability to swallow pills\n* Absolute neutrophil count (ANC) >= 750/mm^3 (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n\n  * NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement\n* White blood cell (WBC) =< 25 x 10^9/L prior to initiation of study therapy. Cytoreduction with hydroxyurea prior to treatment and/or during cycle 1 may be required (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* Platelets >= 75,000/mm^3\n\n  * NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement\n* Total bilirubin =< 1.5 X upper limit of normal (ULN) (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* Aspartate aminotransferase (AST) =< 3.0 x ULN (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* Alanine aminotransferase (ALT) =< 3.0 x ULN (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* Creatinine clearance of >= 45 ml/min per 24-hour urine test or the Cockcroft-Gault formula (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* If in the absence of anticoagulants: International normalized ratio (INR) OR prothrombin (PT) =< 1.5 x ULN (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* If in the absence of anticoagulants: Activated partial thromboplastin time (aPTT) =< 1.5 x ULN (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* Left ventricular ejection fraction (LVEF) >= 50%\n\n  * Note: To be performed within 28 days prior to day 1 of protocol therapy\n* Corrected QT interval (QTc) =< 480 ms\n\n  * Note: To be performed within 28 days prior to day 1 of protocol therapy\n* Seronegative for human immunodeficiency virus (HIV) antigen (Ag)/antibody (Ab) combo, hepatitis C virus (HCV), active hepatitis B virus (HBV) (surface antigen negative), and syphilis (RPR) (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n\n  * If positive, Hepatitis C RNA quantitation must be performed\n* Meets other institutional and federal requirements for infectious disease titer requirements\n\n  * Note Infectious disease testing to be performed within 28 days prior to day 1 of protocol therapy\n* Women of child-bearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months (males) and 6 months (females) after the last dose of protocol therapy\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)\nHealthy volunteers allowed\nMust have minimum age of 16 Years",
    "exclusion_criteria": "* Hematopoietic stem cell transplant within 100 days prior to day 1 of protocol therapy\n* Chemotherapy, radiation therapy, biological therapy, or immunotherapy within 14 days or 5 half-lives, whichever is shorter, prior to day 1 of protocol therapy with the following exceptions:\n\n  * Subjects will be allowed to have been on venetoclax at screening and remain on it through treatment start.\n  * Hydroxyurea is allowed prior to treatment and through cycle 1 for control of rapidly progressing leukemia\n* Strong or moderate CYP3A4 inducers within 14 days prior to day 1 of protocol therapy\n* Grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or star fruit consumed within 3 days prior to the first dose of study drug\n* Immunosuppressants (steroids =< 10 mg/day of oral prednisone or equivalent is allowed) within the last 28 days\n* Hematopoietic growth factors in the last 14 days\n* Must not have received or planning to receive live vaccine while being on study or 4 weeks before and after completion of treatment\n* Herbal medications known to affect platelet function within 14 days of therapy initiation\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent\n* Active graft-versus-host-disease (GVHD)\n* Active central nervous system (CNS) disease\n* No measurable disease in the bone marrow\n* Active diarrhea\n* Gastrointestinal disorder that interferes with oral drug absorption such as malabsorption syndrome\n* Clinically significant cardiac morbidities (class III/IV cardiovascular disability according to the New York Heart Association classification, arrhythmia not stable on medical management, acute cardiovascular ischemic event within 6 months of enrollment, etc.)\n* Clinically significant uncontrolled illness\n* Active infection requiring antibiotics\n* Active/uncontrolled HIV infection, acquired immunodeficiency syndrome (AIDS), or currently taking contraindicated medications for HIV control\n* Diagnosis of Gilbert's disease\n* Any other active malignancy at time of enrollment. Exceptions include basal/squamous cell carcinoma, in situ adequately treated breast and uterine cancer\n* Females only: Pregnant or breastfeeding\n* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
    "miscellaneous_criteria": ""
}